97 related articles for article (PubMed ID: 19796076)
1. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors.
Richardt-Pargmann D; Vollmer J
Ann N Y Acad Sci; 2009 Sep; 1175():40-54. PubMed ID: 19796076
[TBL] [Abstract][Full Text] [Related]
2. RNA targeted therapeutics for hematologic malignancies.
Gewirtz AM
Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
[TBL] [Abstract][Full Text] [Related]
3. Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma.
Fuessel S; Meye A; Kraemer K; Kunze D; Hakenberg OW; Wirth MP
Eur Urol; 2007 Feb; 51(2):315-26; discussion 326-7. PubMed ID: 16935415
[TBL] [Abstract][Full Text] [Related]
4. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
[TBL] [Abstract][Full Text] [Related]
5. [In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma].
Kunze D; Füssel S; Meye A; Wuttig D; Krämer K; Kotzsch M; Toma M; Schwenzer B; Kausch I; Jocham D; Hakenberg OW; Grimm MO; Wirth MP
Urologe A; 2007 Sep; 46(9):1289. PubMed ID: 17665160
[No Abstract] [Full Text] [Related]
6. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
7. DNAzymes and their therapeutic possibilities.
Chan CW; Khachigian LM
Intern Med J; 2009 Apr; 39(4):249-51. PubMed ID: 19402864
[TBL] [Abstract][Full Text] [Related]
8. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis.
Santiago FS; Khachigian LM
J Mol Med (Berl); 2001 Dec; 79(12):695-706. PubMed ID: 11862313
[TBL] [Abstract][Full Text] [Related]
9. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Thomas M; Kularatne SA; Qi L; Kleindl P; Leamon CP; Hansen MJ; Low PS
Ann N Y Acad Sci; 2009 Sep; 1175():32-9. PubMed ID: 19796075
[TBL] [Abstract][Full Text] [Related]
10. [Basic principles of the antisense strategy].
Tauşer RG; Stoica O
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):483-6. PubMed ID: 14756049
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: LErafAON, NeoPharm.
Moreira JN; Simões S
Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
[TBL] [Abstract][Full Text] [Related]
12. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.
Sepp-Lorenzino L; Ruddy M
Clin Pharmacol Ther; 2008 Nov; 84(5):628-32. PubMed ID: 18800034
[No Abstract] [Full Text] [Related]
14. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
[TBL] [Abstract][Full Text] [Related]
15. Antisense phosphorothioate oligodeoxynucleic acid for CD10 suppresses liver metastasis of colorectal cancer.
Luo Y; Fujii K; Ohmori H; Sasahira T; Moriwaka Y; Isobe M; Kuniyasu H
Pathobiology; 2009; 76(5):267-73. PubMed ID: 19816087
[TBL] [Abstract][Full Text] [Related]
16. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.
Lan T; Putta MR; Wang D; Dai M; Yu D; Kandimalla ER; Agrawal S
Biochem Biophys Res Commun; 2009 Aug; 386(3):443-8. PubMed ID: 19523922
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial, selective and reversible control of gene expression using oligodeoxynucleotides in a cell-free protein synthesis system.
Keum JW; Ahn JH; Kang TJ; Kim DM
Biotechnol Bioeng; 2009 Feb; 102(2):577-82. PubMed ID: 18767195
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides.
Klinman DM; Tross D; Klaschik S; Shirota H; Sato T
Ann N Y Acad Sci; 2009 Sep; 1175():80-8. PubMed ID: 19796080
[TBL] [Abstract][Full Text] [Related]
19. Sweet delivery - sugar translocators as ports of entry for antisense oligodeoxynucleotides in plant cells.
Sun C; Ridderstråle K; Höglund AS; Larsson LG; Jansson C
Plant J; 2007 Dec; 52(6):1192-8. PubMed ID: 17922813
[TBL] [Abstract][Full Text] [Related]
20. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides.
Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK
Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
